X4 Pharmaceuticals to Participate in the 36th Annual Piper Sandler Healthcare Conference

XFOR 11.26.2024

Full Press ReleaseSEC FilingsOur XFOR Tweets

About Gravity Analytica

Recent News

  • 01.13.2025 - X4 Pharmaceuticals and Norgine Enter into Exclusive Licensing Agreement to Commercialize Mavorixafor in Europe, Australia, and New Zealand
  • 12.04.2024 - X4 Pharmaceuticals to Present Trial-in-Progress Poster on Phase 3 Study of Mavorixafor in Chronic Neutropenia at 66th ASH Annual Meeting & Exposition
  • 12.03.2024 - X4 Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Recent Filings

  • 01.16.2025 - S-8 Securities to be offered to employees in employee benefit plans
  • 01.13.2025 - 8-K Current report
  • 01.13.2025 - EX-99.1 EX-99.1

BOSTON,Nov. 26, 2024(GLOBE NEWSWIRE) --X4 Pharmaceuticals(Nasdaq: XFOR), a company driven to improve the lives of people with rare diseases of the immune system, today announced that management will participate in the 36thAnnualPiper Sandler Healthcare Conference, taking place inNew York, NYonDecember 3-5, 2024.

36thAnnualPiper Sandler Healthcare Conference
Date:Tuesday, December 3, 2024
Time:11:00AM ET
Format:Fireside Chat
Location:Lotte New York Palace,New York
Webcast Link

This live webcast will also be accessible through “events & presentations” page of the investors section of X4 Pharmaceuticals’ website. After the conclusion of the conference, a replay of this webcast will be available through the same link.

The Company will be available for one-on-one meetings during this conference. Interested investors should contact their Piper Sandler representative to request meetings.

AboutX4 PharmaceuticalsX4 is delivering progress for patients by developing and commercializing innovative therapies for those with rare diseases of the immune system and significant unmet needs. Leveraging our expertise in CXCR4 and immune system biology, we have successfully developed mavorixafor, which has receivedU.S.approval as XOLREMDI®(mavorixafor) capsules in its first indication. We are also evaluating the use of mavorixafor in additional potential indications. X4 corporate headquarters are inBoston, Massachusettsand our research center of excellence is inVienna, Austria. For more information, please visit our website atwww.x4pharma.com.

Company Contact:José JuvesHead of Corporate & Patient Affairsjose.juves@x4pharma.com

Investor Contact:Daniel FerryManaging Director,LifeSci Advisorsdaniel@lifesciadvisors.com(617) 430-7576

Primary Logo

Source: X4 Pharmaceuticals

Please be aware that the following content has been generated by an AI system and may contain errors, inconsistencies, or outdated information. It is provided as-is without any warranties or guarantees of accuracy. We strongly recommend using this content as a starting point for further research and consultation with relevant experts or authorities. We disclaim any liability for damages or losses resulting from the use or reliance on this content.Please note that this is a beta version of the Gravity Analytica LLC’s AI Service which isstill undergoing final testing before its official release. Theplatform, its software and all content found on it are provided on an“as is” and “as available” basis. Gravity Analytica LLC does not give any warranties,whether express or implied, as to the suitability or usability of thisservice, webpage, or its software or any of its content.Should you encounter any bugs, glitches, lack of functionality orother problems on the website, please let us know immediately so wecan rectify these accordingly. Your help in this regard is greatlyappreciated! You can write to us at this addressteam@gravityanalytica.com